In addition, a recent study reported that p21 levels were proportional to CDK4/6 inhibitor sensitivity and had the potential as a monitoring marker for ribociclib, an FDA-approved CDK4/6 inhibitor in late-stage breast cancer [30]. Here, CDK4 is linked to breast carcinoma.